This reflects the poor understanding of the exact risk of ovarian cancer and the typical age of onset in women with PVs in BRIP1, RAD51C, and RAD51D. Given the severity of the intervention and associated side-effects, patients and health care providers have strong interest in delaying RRSO until older ages if safe. This evidence concerns the gene BRIP1 and ovarian cancer.